Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp lthough primary cardiac hypertrophy can result from genetic abnormalities, most cases in the clinical situation are secondary to pressure or volume overload, to mutations of sarcomere proteins, or to loss of contractile mass because of a prior infarction. 1 When cardiac hypertrophy persists for a long time without intensive care, the resulting deterioration in diastolic function often leads to congestive heart failure. 2 Great advances in surgical techniques and medical management of congenital heart diseases have dramatically improved the survival of affected patients over the past decades. However, with many patients with congenital heart disease now surviving until adulthood, right ventricular hypertrophy (RVH) has drawn much attention. 3 It is well known that several congenital heart diseases often cause RVH, even though various surgical or interventional corrections have been developed. Examples are pressure overload RVH caused by right ventricular (RV) outflow tract obstruction after total correction of tetralogy of Fallot, pulmonary stenosis, the atrial switch operation for transposition of the great arteries, and congenitally corrected transposition of the great arteries, and systemic RVH after the Fontan operation. Other conditions are volume overload RVH caused by atrial septal defect, tricuspid regurgitation, and pulmonary regurgitation. 3,4 Development of RVH should be carefully monitored and both medical prevention and treatment should be considered.
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Currently, afterload-reducing agents, β-adrenergic blockers, inotropics, and diuretics are used in the treatment of cardiac dysfunction, including cardiac hypertrophy. It is widely accepted that several angiotensin-converting enzyme (ACE) inhibitors have clinical benefits in the treatment of left ventricular hypertrophy (LVH) 5-7 but there is much debate over the ideal medical management of RVH 4 because the primary Sodium Valproate Prevents RVH target tissues of agents such as ACE inhibitors are the systemic circulation rather than the heart itself or the pulmonary circulation, which limits their therapeutic application to RVH.
Recently, several independent research groups, including ours, have demonstrated that histone deacetylase (HDAC) inhibitors prevent cardiac hypertrophy. 8- 12 We also demonstrated that HDAC inhibitors reverse established hypertrophy. 10 In follow-up studies, we elucidated that activation of HDAC2, a class I HDAC, plays a key role in the development of hypertrophy, 13 which suggests a novel therapeutic role of histone modifiers in detrimental cardiac diseases. However, the effects of those inhibitors on RVH have not been studied.
Therefore, in the present study, we evaluated the effects of sodium valproate, an HDAC inhibitor, on RVH induced in rats by either pulmonary artery banding (PAB) or monocrotaline (MCT) injection. MCT is well known to selectively induce pulmonary endothelial injury, which causes RVH secondary to pulmonary arterial hypertension. 14- 16 We also compared the effects of the HDAC inhibitor with those of captopril, a conventional ACE inhibitor.
Methods

RVH Model
Three-week-old male Sprague-Dawley rats were purchased from Daehan Biolink (Daejeon, Korea) and housed individually in plastic cages in a temperature-controlled room. The investigation conformed to the Guide for the Care and Use of Laboratory Animals (US National Institutes of Health: NIH Publication No. 85-23, revised 1996). The experimental protocol was approved by the Chonnam National Medical School Research Institutional Animal Care and Use Committee. All surgical procedures, electrocardiography, and echocardiography were performed with the animals under anesthesia induced by ketamine (16.65 mg/kg IM) and xylazine (7.77 mg/kg IM).
For PAB, the midline sternum was opened under anesthesia. Partial pulmonary arterial constriction was performed Representative RT-PCR analysis of heart mRNA from rats in the sham, 7-day PAB, and 14-day PAB groups. (E) ECG configuration changes in PAB rats: T waves in the V1 standard lead are inverted. **P<0.01, *P<0.05. Error bars indicate SEM. Numbers below the abscissa represent the numbers of rats tested. (F) M-mode echocardiographic findings of rat heart treated with either vehicle or MCT injection for 3 weeks. (G) Gross findings of rat heart treated with MCT injection for 3 weeks. (H) ECG configuration changes in the MCT injection rats: T waves in the V1 standard lead are inverted at 21 days after injection.
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by ligation of the main pulmonary artery with a 4-0 braided polyester suture with a 22-gauge needle. The increase in blood flow velocity was confirmed by Doppler echocardiography just after the operation ( Figure 1A) . Sham-operated animals underwent the same surgical procedure without constriction of the pulmonary artery. RVH was confirmed by the following indexes: (1) echocardiography ( Figure 1A) , (2) electrocardiography (Figure 1E) , (3) ratio of RV free wall weight to left ventricular (LV) free wall and interventricular septal (IVS) wall weight [RV/(LV+IVS)], and (4) ratio of RV wall weight to body weight (RV/BW) at 3 weeks after the operation.
MCT (Sigma, St Louis, MO, USA) was dissolved in 1 mol/L HCl, neutralized with 0.5 mol/L NaOH, and then diluted with distilled water to pH 6.8-7.2 for use. MCT was given to rats as a single subcutaneous injection of 30 mg/kg 
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(MCT group) whereas 0.9% saline was used for control animals (vehicle group).
Hematoxylin-eosin staining (Sigma) was performed at 2 or 3 weeks after PAB or MCT injection. Masson's trichrome staining (Sigma) was also performed as described previously. 17 Images were obtained and digitized with an Olympus CX31 microscope equipped with an Infinity 1 camera (Lumenera Scientific, Ottawa, Canada). The density of collagen, shown as blue or green, was calculated using an image analysis system (NIS-Elements AR 3.0, Nikon) and the sum of the all collagen areas was divided by the total area. 18
Echocardiography and Electrocardiography
Echocardiographic studies were performed with a 15-MHz linear array transducer system (Acuson Sequoia c512, Siemens and iE33 system, Philips Medical Systems). 17,19 Two-dimensional (2-D)-guided M-mode of the RV was obtained from the parasternal view. The RV cavity dimension and thickness of the RV free and IVS walls were measured, and the percent change in RV dimension [fractional shortening (FS), RV%FS] was calculated as: RV%FS = [(RVDd − RVDs)/ RVDd] ×100, where RVDd is the RV dimension at end-diastole and RVDs is the RV dimension at end-systole. The diameter of the inferior vena cava (IVC) was also measured by 2-D echocardiography. The RV Tei index was calculated as a myocardial performance index: RV Tei index = (RV isovolumic contraction time + RV isovolumic relaxation time)/ RV ejection time. 20 Pulsed-wave Doppler echocardiography was recorded in the main pulmonary artery and acceleration time was measured from the onset of flow to the time of peak velocity. 21 The 6-limb lead ECG and 2-chest lead ECG, similar to leads V1 and V6 in humans, were recorded while the animals were anesthetized. Each rat was fixed in position on its back on a pad, and the ECG was recorded by the ECG module (PageWriter 200i, Hewlett Packard, USA) every week.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Immunoblotting
Total RNA was isolated with TriZol reagent (Invitrogen, Carlsbad, CA, USA), and 1 μg of RNA was subjected to reverse transcription reaction with the Superscript firststrand synthesis system in a RT-PCR kit (Invitrogen). For Western blotting, anti-atrial natriuretic factor (ANF) (1:1,000, Biodesign, Saco, ME, USA), anti-α-tubulin antibody (1:1,000, Zymed, South San Francisco, CA, USA), anti-actin antibody (1:1,000, Sigma), anti-acetyl histone H3 antibody (1:20,000, Upstate Biotechnology Inc, Lake Placid, NY, USA), antiHdac1 antibody (1:1,000; Abcam, Cambridge, MA, USA), anti-Hdac2 antibody (1:1,000; Zymed), anti-Hdac3 antibody (1:1,000; Abcam) or anti-Hdac8 antibody (1:1,000; Abcam) was used.
Histones were isolated from the RV as described previously, using nuclear extraction kits (Panomics Inc, Fremont, CA, USA). 10 The loading amounts were visualized by Coomassie staining after transferring the proteins to nitrocellulose membranes.
Sodium Valproate Administration in the RVH Model
PAB rats were divided into 2 groups: 1 group was administered sodium valproate (Sigma) after PAB through the drinking water (0.71% weight/vol) ad libitum, as described previously, 17 while the second group was treated with vehicle only. The MCT-treated rats were also divided into 2 groups, with 1 group treated with sodium valproate as described above. RVH was then evaluated as described.
ACE Inhibitor in PAB
Rats were separated into 3 groups: (1) sham-operated controls, (2) PAB with no therapy, and (3) PAB with 20 mg · kg -1 · day -1 of the ACE inhibitor captopril. 22 Captopril (Sigma) was dissolved in dimethyl sulfoxide (Sigma) and then diluted to the desired concentration. For the administration of captopril, an osmotic pump (Alzet ® , Durect Corp, Cupertino, CA, CHO YK et al.
USA) placed subcutaneously the next day after surgery. Doses of 10-20 mg · kg -1 · day -1 are known to be sufficient for inhibiting ACE, 22-25 so we administered 20 mg · kg -1 · day -1 captopril to the rats. To confirm inhibition of ACE, we measured the plasma concentrations of angiotensin I and angiotensin II by radioimmunoassay (Green Cross Reference Lab, Daejeon, South Korea). The dose of captopril administered (20 mg · kg -1 · day -1 ) successfully reduced plasma angiotensin II concentrations, but increased angiotensin I levels (data not shown).
Regression of RVH was evaluated by RV/BW or RV/(LV + IVS) ratios and by echocardiography and electrocardiography. ECGs were recorded on the 14 th day after the operation. 
Statistical Analysis
Results
RVH Induced by PAB
On echocardiography, PAB induced a marked increase in main pulmonary artery flow velocity because of the suprapulmonary artery stenosis compared with the sham-operated rats ( Figure 1A) . The thickness of both the RV free and IVS free walls also increased, whereas the IVS was flattened. Hematoxylin-eosin staining of PAB rat heart showed increased RV free wall thickness and a flattened IVS ( Figure 1B) . RVH was further confirmed by measuring RV weight; compared with sham-operated rats, RV/BW and RV/(LV+IVS) increased by 125% and 99%, respectively (Figures 2A,B ; Table 1 ). PAB dramatically increased the levels of α-tubulin, an alternate protein marker of hypertrophy, 26 in the rat RV ( Figure 1C) . The transcription levels of myosin heavy polypeptide (Myh7, also known as β-myosin heavy chain) and natriuretic polypeptide type A (Nppa, which encodes ANF), both hallmarks of cardiac hypertrophy, were increased in PAB rats by increasing the duration of PAB (Figure 1D) .
The ECG configurations in the PAB rats were also significantly changed. Compared with the sham rats, T waves in the V1 standard lead were inverted and the amplitude of negative T waves was further increased at 14 days after the operation compared with 7 days (Figures 1E,S1A) .
RVH Induced by MCT
A single injection of MCT was enough to induce RVH 3 weeks later, and it was documented by the increased thickness of both the RV free and IVS walls and by deviation of the IVS to the LV free wall on echocardiography (Figures 1F,  4D) . The development of RVH was further confirmed by a 85% increase in the RV/BW ratio and a 78% increase in the RV/(LV+IVS) ratio (Figures 4B, C; Table 2 ). The gross findings in the MCT-injection rats revealed enlargement of the RV, predominantly in the RV infundibulum ( Figure 1G) . Changes in the ECG configurations were also studied. In contrast with PAB, the T wave change in lead V1 was not prominent until 14 days after injection; however, it was dramatically inverted at 3 weeks (Figures 1H,S1B ).
Attenuation of PAB-Induced RVH by Sodium Valproate
To determine whether RVH induced by pressure overload in rats could be prevented by HDAC inhibition, we treated PAB rats with sodium valproate, which significantly attenuated the RV/BW and RV/(LV+IVS) ratios by 26% and 20%, respectively, compared with PAB only rats (Figures 2A, B ; Table 1 ).
On echocardiography, sodium valproate attenuated the change in the thickness of the RV free and IVS walls and it also reduced the IVS wall flattening (Figures 2C,D; Table 1 ). The RV Tei index was unchanged with either PAB or sodium valproate administration. However, pulmonary artery flow acceleration times in the PAB rats were reduced after administration of sodium valproate ( Table 1) , which suggests functional improvement by the drug. The increase in diameter of the IVC, a marker of venous congestion, was recovered by sodium valproate treatment ( Figure 2E ; Table 1 ). The PAB-induced inversion of T waves in the V1 standard lead of ECG was slightly blunted by sodium valproate treatment ( Figure 2F) .
Hematoxylin-eosin staining of PAB rat heart showed an increase in RV free wall thickness and a flattening of the IVS, which were recovered by administration of sodium valproate ( Figure 3A) . PAB for 3 weeks caused fibrosis of the myocardium, as demonstrated by Masson's trichrome staining; however, fibrosis was recovered by sodium valproate administration ( Figure 3B) . The transcription levels of Myh7 and Nppa in PAB rats were attenuated by sodium valproate treatment ( Figure 3C) .
To evaluate the ability of sodium valproate as a HDAC inhibitor, the levels of acetylation of histones were measured by use of anti-acetyl histone H3 specific antibody after the isolation of histones from the RV. PAB reduced the acetylation of histone H3, but administration of sodium valproate dramatically increased the acetylation of histone H3 in the RV (Figure 3D) .
Sodium valproate attenuated the levels of protein markers of cardiac hypertrophy such as ANF and α-tubulin in PAB rats ( Figure 3E) . However, the amounts of Hdac1, Hdac2, Hdac3, and Hdac8 proteins were unchanged in response to either hypertrophic stimuli or administration of HDAC in- 
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hibitor ( Figure 3E ).
Attenuation of MCT-Induced RVH by Sodium Valproate
In the MCT-induced RVH rats, hematoxylin-eosin staining showed that the changes in RV free wall thickness and the flattening of the IVS were attenuated by sodium valproate administration ( Figure 4A) . Compared with control rats, sodium valproate administration significantly reduced the RV/BW and RV/(LV+IVS) ratios by 31% and 29%, respectively (Figures 4B,C ; Table 2 ). Sodium valproate itself did not affect the RV/BW and RV/(LV+IVS) ratios of vehicle rats (data not shown). On echocardiography, the thickness of both the RV free and IVS walls in MCT-injection rats was attenuated by the administration of sodium valproate (Figures 4D,E; Table 2 ). The RV Tei index was unchanged by either MCT injection or sodium valproate administration. However, the pulmonary artery flow acceleration times in the MCT rats were decreased, and this was attenuated by administration of sodium valproate ( Figure 4F; Table 2 ). Interestingly, the T wave inversion was completely recovered to a positive value similar to the control rats ( Figure 4G ).
ACE Inhibitor in PAB-Induced RVH
To determine whether an ACE inhibitor can block RVH induced by pressure overload, we treated PAB rats with captopril. Hematoxylin-eosin staining revealed that captopril administration did not reduce the PAB-induced increase in Table 3 ). On echocardiography, the thickness of both the RV free and IVS walls of PAB rats was not recovered by captopril administration (Figures 5D,E; Table 3 ). The failure to improve RVH was also documented by ECG; the inverted T waves in the V1 standard lead in PAB rats were not attenuated by captopril treatment (Figure 5F ). Captopril also did not attenuate the PAB-induced increase in the transcription levels of Myh7 and Nppa ( Figure 5G ).
Masson's trichrome staining revealed that captopril administration failed to reduce the fibrosis in the ventricular myocardium of PAB rats (Figures 5H,I ). The evaluation of other parameters consistently revealed that RVH was not reduced by captopril (Table 3) .
Discussion
Our results clarify that sodium valproate, an HDAC inhibitor, has a cardioprotective effect in RVH induced by pressure overload; the HDAC inhibitor attenuated RVH induced by either PAB or MCT injection. However, captopril, an ACE inhibitor, did not show any beneficial effect on RVH in PAB rats.
When the RV is exposed to pressure overload by either pulmonary hypertension or RV outflow tract obstruction, progressive contractile dilation follows an initial adaptive response that includes RVH. 4 Although some evidence shows that hypertrophy itself is beneficial for overcoming the increased backward pressure, 1,27 it is well accepted that persistent increase in pressure and the size of the RV causes a loss of contractile force to pump out the blood. Moreover, considering that persistent, uncorrected RV failure often induces diastolic dysfunction of the LV, which then results in a detrimental loss of cardiac output and ultimately heart failure, many therapeutic approaches to curing RVH are required. 4 Thus, many researchers are eager to find a cure for RV dysfunction, and several animal models of RV dysfunction, including RVH, are used.
Several fetal genes that are expressed only during embryonic heart development are reactivated in cardiac hypertrophy. 28 Because posttranslational modifications of histone proteins are a key mechanism of the transcriptional regulation of downstream genes, 29 it is highly possible that modification of histones is also involved in activation of the fetal gene program in the development of heart diseases. Among the histone modifications, histone acetylation/deacetylation has been the most extensively investigated mechanism. 30 HDACs, which mediate the deacetylation of histone, are divided into 4 classes: class I (Hdac1, 2, 3, and 8), class II (Hdac4, 5, 6, 7, and 10), class III (Sirt1-7), and class IV (Hdac11). 31 Histone deacetylation is closely related to heart diseases, including cardiac hypertrophy and heart failure. 32 Including our group, many researchers have repeatedly shown that chemical HDAC inhibitors block cardiomyocyte hypertrophy or LV pressure overload cardiac hypertrophy. 8-12, 17 Because HDACs are important targets of cellsignaling cascades, with regard to the activation of gene expression in cardiac hypertrophy and in ischemia/reperfusion injury, 1 they are of great interest as therapeutic targets in various cardiac diseases, including cardiac hypertrophy. However, to our knowledge, therapeutic application of HDAC inhibitors to RVH has yet to be investigated. In the present study, for the first time, we demonstrate that an HDAC inhibitor was effective in the treatment of RVH.
The renin-angiotensin-aldosterone system (RAS) is an important physiologic system involved in the development of cardiac hypertrophy. 33 Many clinical and experimental studies have proved that ACE inhibitors and angiotensin type 1 receptor blockers reduce cardiac abnormalities and thereby improve hemodynamics in cardiac diseases such as chronic heart failure, LVH, and myocardial infarction. 5-7,34,35 Also, captopril, an ACE inhibitor, has been reported as beneficial in the treatment of high blood pressure and cardiac hypertrophy. 7,36-38 Moreover, in a spontaneously hypertensive rat model, Chen et al 39 reported that captopril reduced hypertrophy-dependent gene expression; they observed that Nppa and c-myc transcript levels were reduced by captopril treatment. However, those studies investigated the LV not the 
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RV. Considering that the primary action of ACE inhibitors is to reduce afterload by dilatation of peripheral blood vessels, those effects reported by Chen et al might be caused by indirect effects on blood vessels, rather than by direct cardiac effects. Thus, the question is raised whether ACE inhibitors would also be effective at blocking RVH secondary to pulmonary circulation. Indeed, although investigators have tried to find a protective property of ACE inhibitors or the RAS in a RV pressure overload animal model, 2 debate still exists as to whether these agents are effective or not. For example, ramipril, an alternate ACE inhibitor, did not sufficiently improve RVH in PAB rabbits. 40 In addition, the lack of an increase in systemic RAS activity in PAB-induced RVH 2,41 may explain why ACE inhibitors do not have a beneficial effect on RVH. Likewise, in the present study we did not observe any significant improvement of RVH by administration of an ACE inhibitor. In contrast, administration of an HDAC inhibitor dramatically reduced RVH. It is noteworthy that the therapeutic target of HDAC inhibitors is the heart itself rather than the systemic circulation, 10 which differs from ACE inhibitors, which affect the systemic circulation. Sodium valproate is an anticonvulsant used in the treatment of epilepsy, bipolar disorder, and other psychiatric conditions. It also produces changes in the expression of multiple transcription genes by inhibition of HDAC. 42, 43 Because sodium valproate has been widely used clinically, it would not be difficult to extend its therapeutic application to cardiovascular diseases such as RVH.
Study Limitations
We did not treat with angiotensin type 1 receptor blockers, which directly inhibit angiotensin II, and we only treated with captopril or sodium valproate for a relatively short period. We did not test other well-known HDAC inhibitors, such as trichostatin A. Nevertheless, this study highlights the need to search for new therapeutic possibilities of HDAC inhibitors against RVH. Future studies with a wide range of application modalities and using various HDAC inhibitors will give us a better understanding of their beneficial effects.
